
Sign up to save your podcasts
Or


What is clinical problem with regard to leaflet thrombosis after TAVR, and what are the main findings of the ADAPT-TAVR trial?
In this interview, Duk-Woo Park, MD and Sun Moon Kim MD, with Zaid I. Almarzooq MBBCh, discuss Late Breaker: Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial.
By American College of Cardiology3.8
5454 ratings
What is clinical problem with regard to leaflet thrombosis after TAVR, and what are the main findings of the ADAPT-TAVR trial?
In this interview, Duk-Woo Park, MD and Sun Moon Kim MD, with Zaid I. Almarzooq MBBCh, discuss Late Breaker: Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial.

137 Listeners

320 Listeners

498 Listeners

169 Listeners

885 Listeners

289 Listeners

140 Listeners

1,156 Listeners

41 Listeners

195 Listeners

90 Listeners

364 Listeners

431 Listeners

371 Listeners

32 Listeners